← Back to feedRead original →
VERIFIEDMint Companies·neutral
US generics tariffs more negotiation tactic than real threat: Biocon’s Kiran Mazumdar-Shaw
AI Summary
- ·Biocon's Kiran Mazumdar-Shaw views US generics tariffs as a negotiation tactic.
- ·The company is in a wait-and-watch mode regarding the tariffs.
- ·Biocon is exploring partnerships for US manufacturing if necessary.